Effigene Pharmaceuticals, Inc. ("Effigene") is a biopharmaceutical company that focuses on improving the utilization of RNA interference (RNAi) technology and facilitating the development of small interference RNA (siRNA)-based therapeutics to treat various human diseases.

EFI-001™ is a proprietary formulation for enhancing silencing effects of siRNA or shRNA in eukaryotic cells.